CSL Ltd. — Regulatory Filings 2013

Oct 6, 2013

For immediate release 7 October 2013

==> picture [205 x 32] intentionally omitted <==

==> picture [59 x 30] intentionally omitted <==

==> picture [262 x 27] intentionally omitted <==

Agreement to settle U.S. antitrust class action litigation Profit outlook re-affirmed, subject to settlement

CSL Limited (ASX:CSL) today announced that it has signed an agreement to settle the U.S. antitrust class action litigation, filed by certain U.S. and Puerto Rican hospital groups, which has been ongoing since 2009. The settlement agreement resolves and dismisses all claims and potential claims of class members against CSL in the lawsuit, as well as those against the Plasma Protein Therapeutics Association, an industry trade association.

The settlement, including payment of US$64m, is subject to an approval process by the U.S. federal court. This process is expected to take several months during which time CSL’s involvement in the litigation will be on hold.

Commenting on the settlement, CSL’s Chief Executive Officer and Managing Director Paul Perreault said, “While we continue to strongly reject any allegation of wrong doing, we have negotiated a settlement of the litigation which we believe is in the best interests of the Company and our shareholders. To pursue the case further would have required several more years of management time and focus as well as substantial additional legal costs with no absolute certainty of the outcome.”

Profit outlook[1] (at 2012/2013 exchange rates[2] )

The Company continues to anticipate net profit after tax (NPAT) growth in line with the guidance provided at the Company’s full year result announced on 14 August 2013, subject to today’s announcement regarding the settlement of the U.S. antitrust litigation.

If approved, the settlement represents a one-off charge reducing NPAT expectations for fiscal 2014 by US$39m. This charge takes anticipated NPAT growth for the current financial year to approximately 7%, at 2012/2013 exchange rates[2] .

1 In compiling the Company’s financial forecasts for the year ending 30 June 2014 a number of key variables which may have a significant impact on guidance have been identified. These include material price and volume movements in plasma products, competitor activity, changes in healthcare regulations and reimbursement policies, royalties arising from the sale of Human Papillomavirus Vaccine, internationalisation of the Company’s influenza vaccine sales and plasma therapy life cycle management strategies, enforcement of key intellectual property, regulatory risk, litigation, the effective tax rate and foreign exchange movements.

==> picture [99 x 7] intentionally omitted <==

==> picture [59 x 30] intentionally omitted <==

==> picture [262 x 27] intentionally omitted <==

Page 2

7 October 2013

Teleconference

CSL will today, at 2pm (Australian Eastern Standard Time), hold a conference call to provide additional background to today’s announcement and answer any questions that may arise.

Dial in details - Australia: 1800 059 809 International: +61 7 3145 4003

For further information, please contact:

Investors: Media: Mark Dehring Sharon McHale Head of Investor Relations Senior Director Public Affairs CSL Limited CSL Limited Telephone: +613 9389 2818 Telephone: +613 9389 1506 Email: mark.dehring@csl.com.au Mobile +614 0997 8314 Email: sharon.mchale@csl.com.au

Tim Duncan Hintons & Associates Phone: +613 9600 1979 Mobile: +614 0844 1122 Email: tduncan@hintons.com.au

2 Using 2012/2013 exchange rates removes the impact of exchange rate movements to facilitate comparability. See Company 2012/2013 results announcement for further detail.

==> picture [99 x 7] intentionally omitted <==